KRAS and carcinoma: KRAS mutations were detected in 45/73 non-PPE samples (61.64%); the frequencies of which were significantly different among normal (43.18%), hyperplasia (87.50%), EAH (90.91%), and carcinoma lesions (55.56%, P < 0.01, Table 3).